60
Zhejiang Medicine
600216.SS·SSEShaoxing CNFounded 199912,000 employees
Mid CappharmaPublicOncologyMetabolic
Platform: Vitamin API
Market Cap
$3B
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (600216.SS)
Loading 600216.SS stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| 600-5291 | 600-5291 | Phase 2 | 2 | LAG-3 | OCDParkinson's | ||
| Sotoglumide | 600-9555 | Phase 1/2 | 1 | ALK | Angelman | ||
| Semacapivasertib | 600-4200 | Preclinical | 2 | CDK4/6 | RBAML |
SEC Filings & Financial Documents
SEC filings are not available for SSE-listed companies.
Zhejiang Medicine trades on SSE (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (5)